Fatima Laher to Antibodies, Neutralizing
This is a "connection" page, showing publications Fatima Laher has written about Antibodies, Neutralizing.
Connection Strength
0,825
-
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. PLoS Med. 2020 02; 17(2):e1003038.
Score: 0,570
-
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. PLoS Med. 2020 05; 17(5):e1003117.
Score: 0,145
-
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition. EBioMedicine. 2023 Jul; 93:104590.
Score: 0,045
-
Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk. PLoS Pathog. 2021 03; 17(3):e1009363.
Score: 0,038
-
Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS? PLoS Biol. 2016 Mar; 14(3):e1002372.
Score: 0,027